Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8 Triple Negative Breast Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Stomach Neoplasms 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Hemangiosarcoma 1 HER2-positive Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1 Adenocarcinoma 1

Interventions

Bevacizumab 56 Cetuximab 50 Fluorouracil 45 Leucovorin 39 Oxaliplatin 38 pembrolizumab 31 Specimen Handling 27 Irinotecan 25 Magnetic Resonance Spectroscopy 17 Biopsy 17 Nivolumab 15 HMPL-013 13 Folfox protocol 13 Capecitabine 13 Gemcitabine 12 Cisplatin 12 trifluridine tipiracil drug combination 11 Panitumumab 11 Carboplatin 11 Pemetrexed 9 IFL protocol 9 encorafenib 8 balstilimab 8 Standard of Care 8 Paclitaxel 8 Early Intervention, Educational 8 130-nm albumin-bound paclitaxel 8 fludarabine 7 atezolizumab 7 Educational Status 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Colorectal Neoplasms × tucatinib × 90 days × Clear all

NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡